Edwards Lifesciences

At a glance

Edwards Lifesciences reported 2025 revenue of $6.07B, up 11.5% from $5.44B in 2024. Over 4 years since 2021 ($5.23B), that is growth of about 3.8% a year. Operating margin was 20.8%, down from 32.3% in 2021. 2025 was the highest revenue year in this period.

In the last 12 months 9 insiders reported 0 open-market purchases and 41 sales ($27.7M). 23 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $2.9M by CVP, TMTT, Surgical & IHFM Daveen Chopra on Aug 26, 2026.

Edwards Lifesciences filed 7 current reports (Form 8-K) in the last 12 months, most often for officer or director change (3), results of operations (3), shareholder vote results (1) and regulation fd disclosure (1). The latest officer or director change was reported on Aug 28, 2026.

3 of the 20 investors tracked here held Edwards Lifesciences at the last quarter end, worth $117.2M combined. It is the largest weight for Bridgewater Associates (0.1% of its portfolio), followed by National Pension Service (Korea) (0.1%). Added: Bridgewater Associates. Reduced: Renaissance Technologies.

Annual results

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.